The role of platelets in inflammation

MR Thomas, RF Storey - Thrombosis and haemostasis, 2015 - thieme-connect.com
There is growing recognition of the critical role of platelets in inflammation and immune
responses. Recent studies have indicated that antiplatelet medications may reduce mortality …

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention

D Capodanno, R Mehran, M Valgimigli… - Nature Reviews …, 2018 - nature.com
In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly
known as aspirin) has been the mainstay of treatment for decades owing to its capacity to …

Protective effects of ticagrelor on myocardial injury after infarction

G Vilahur, M Gutiérrez, L Casani, L Varela… - Circulation, 2016 - Am Heart Assoc
Background: The P2Y12 receptor antagonist ticagrelor has been shown to be clinically
superior to clopidogrel. Although the underlying mechanisms remain elusive, ticagrelor may …

Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model

MR Thomas, SN Outteridge, RA Ajjan… - … and Vascular Biology, 2015 - Am Heart Assoc
Objective—Clinical studies suggest that platelet P2Y12 inhibitors reduce mortality from
sepsis, although the underlying mechanisms have not been clearly defined in vivo. We …

Translational implications of platelets as vascular first responders

RC Becker, T Sexton, SS Smyth - Circulation research, 2018 - Am Heart Assoc
Platelets play a vital role in normal hemostasis to stem blood loss at sites of vascular injury
by tethering and adhering to sites of injury, recruiting other platelets and blood cells to the …

Association of multiple biomarkers with risk of all-cause and cause-specific mortality after acute coronary syndromes: a secondary analysis of the PLATO biomarker …

D Lindholm, SK James, K Gabrysch, RF Storey… - JAMA …, 2018 - jamanetwork.com
Importance Mortality remains at about 5% within a year after an acute coronary syndrome
event. Prior studies have assessed biomarkers in relation to all-cause or cardiovascular …

Effect of P2Y12 inhibitors on inflammation and immunity

MR Thomas, RF Storey - Thrombosis and haemostasis, 2015 - thieme-connect.com
Platelet P2Y 12 inhibitors form a major part of the treatment strategy for patients with acute
coronary syndromes (ACS) due to the importance of the platelet P2Y 12 receptor in …

Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC …

B Gigante, JH Levy, E van Gorp, A Bartoloni… - European heart …, 2023 - academic.oup.com
Patients with severe infections and a pre-existing indication for antithrombotic therapy, ie
antiplatelet agents, anticoagulant drugs, or their combinations, require integrated clinical …

Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes

G Ducrocq, PJ Schulte, A Budaj, JH Cornel, C Held… - American heart …, 2017 - Elsevier
Background Evaluation of antithrombotic treatments for acute coronary syndromes (ACS)
requires balancing ischemic and bleeding risks to assess net benefit. We sought to compare …

Comparison of clinical outcomes between ticagrelor and clopidogrel in East-Asian patients with acute coronary syndrome: large cohort study

WC Lee, CY Fang, YH Tsai, YY Hsieh, TY Chen… - American Journal of …, 2023 - Springer
Aim A high risk of bleeding is observed in East Asian patients with acute coronary syndrome
(ACS). Therefore, the choice between two antiplatelet therapy drugs, ticagrelor and …